News/Events

Stay up-to-date on the world of marine Omega-3s and everything Epax.

Q2 2018

Pelagia financial results

Q2 2018

Pelagia - Epax' owner - recently released its results for Q2 2018.

Visit Pelagia's webpage for more information! 

Epax to exhibit at Vitafoods Asia

Meet us!

Epax to exhibit at Vitafoods Asia

Epax Norway AS is set to exhibit at Vitafoods Asia September 11-12 at the Sands Expo & Convention Centre at Marina Bay Sands in Singapore. Visit us at stand J30 on the GOED Pavilion for a chat about Omega-3!

Epax is growing

We're looking to fill several new positions

Epax is growing

UPDATE: Application deadline has now passed. 

We currently have 2 positions open at our facility in Ă…lesund, Norway. Join one of the best teams in the Omega-3 industry!  



PUFA level and acute venous thromboembolism

New Omega-3 research

PUFA level and acute venous thromboembolism

Hiki M et al. have studied the significance of serum polyunsaturated fatty acid level imbalance in patients with acute venous thromboembolism, and our key takeway is that high serum AA levels and low EPA levels are associated with the development of acute VTE, suggesting that the imbalance of PUFAs may be a potential therapeutic target for preventing acute VTE.

Background: Polyunsaturated fatty acids (PUFAs) take part in various biological events linked to the pathogenesis of venous thromboembolism (VTE), including inflammation, endothelial dysfunction, and hypercoagulability. Several studies have demonstrated the association between PUFAs and the occurrence of VTE.

Design: 45 patients with acute VTE were enrolled to examine their PUFA levels. 37 age-, gender-, and body mass index-matched healthy volunteers were controls. Serum omega 3 (eicosapentaenoic acid: EPA and docosahexaenoic acid: DHA) and omega 6 (dihomogammalinolenic acid: DGLA and arachidonic acid: AA) fatty acids levels were measured within 24 h of admission.

Results: Patients with VTE showed significantly higher AA and lower EPA levels, and lower EPA/AA ratios than the controls. Multivariate analysis revealed that AA was an independent marker for VTE. When the patients were divided based on their median age (58 years old) the younger patients with VTE showed significantly lower EPA/AA levels than their age-matched controls, whereas older patients with VTE showed a significantly higher AA/DGLA levels than the older controls. 

Source: Journal of atherosclerosis and thrombosis 2017;24:1016-1022